Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs Breeze Meds

AbundRX
Graded #181

Lower grade

vs+5.800000000000011
Breeze Meds
Graded #55

Higher grade

The verdict

Breeze Meds takes it — 72.4/100 to 66.6/100.

Breeze Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Charges nothing until a provider approves you — but keeps its pricing inside the intake.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBreeze Meds +5
67
72
Dose & formulationBreeze Meds +2
64
66
Clinical oversightAbundRX +3
79
76
Labs & monitoringBreeze Meds +7
53
60
FulfillmentBreeze Meds +10
74
84
Contract termsBreeze Meds +31
55
86
AbundRX · left barBreeze Meds · right bar

The numbers

MetricAbundRXBreeze Meds
WeighScore66.6/10072.4/100
GradeCC
Scorecard rank#181#55
Semaglutide$179/mo (compounded)From $199/mo
Tirzepatide$279/mo (compounded)From $299/mo first month, $399/mo thereafter
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #181 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Breeze Meds

Graded #55 · C

Strengths

  • Nothing charged until a provider approves you, and the consult is free if you go ahead
  • One inclusive price covering consult, medication, supplies, shipping and support
  • LegitScript certified, all 50 states, cancel or change plan at any time
  • NAD+ injections offered alongside the GLP-1 line

Where it loses points

  • The public site names no molecule behind its "from $199" — tirzepatide pricing appears only inside the intake
  • Every quoted figure is for the LOWEST dose; the funnel says higher doses may cost more
  • An $80 consultation fee applies if you are approved and then decline
  • Injection only, compounded only, with no published lab programme

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard